The Exchange had sought clarification from Vaishali Pharma Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1.Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed.
VAISHALI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE asked Vaishali Pharma Limited to explain why the financial results it submitted for the quarter ended 30 September 2025 did not follow the format prescribed by SEBI under Regulation 33 of the Listing Rules. The Company has now submitted its response to the exchange. This is a procedural interaction regarding the presentation of quarterly numbers, not a rejection or restatement of results.
This is a routine compliance matter and is unlikely to have any material impact on shareholders or the stock price. Investors should watch for the actual quarterly results when published in the correct SEBI format to assess business performance.